

PA-IDC

QUERY CONTROL FORM		RTIS USE ONLY	
Application No.	09/771,669	Prepared by	MPB
Examiner-GAU	Page - 1615	Date	9/28/04
		No. of queries	4
		Tracking Number	05997841
		Week Date	08/16/04
			1PW(PWT4)

JACKET			
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other <i>Index of claim</i>

SPECIFICATION	MESSAGE
a. Page Missing	① Final column of index of claims is blank (claims renumbered box not marked).
b. Text Continuity	② Continuing data is listed in specification (Amdt. dated 06/09/04) but not shown on the palm/bib sheet.
c. Holes through Data	③ Original claims 7 and 8 both depends on original claim 24. please advise/correct claim dependency.
d. Other Missing Text	④ clean copy of claims (dated 01/07/03, coded as REM, pages 6-8 are illegible - see attached. please provide legible/clearer copies of claim listing.
e. Illegible Text	
f. Duplicate Text	
g. Brief Description	
h. Sequence Listing	
i. Appendix	
j. Amendments	
k. Other	
CLAIMS	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	
d. Incorrect Numbering	
e. Index Disagrees	
f. Punctuation	
g. Amendments	
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
k. Other <i>illegible claim listing</i>	
	<i>Thank you</i> initials <i>MA</i>
	RESPONSE
	initials

CLEAN COPY OF ALL CLAIMS

D1 1. A composition with synergistic anti-inflammatory properties for use in conditions induced by inflammatory disease-causing biomolecules released from mast cells by the activation and degranulation of said mast cells, comprising a non-bovine proteoglycan and unrefined kernel olive oil, and one or more of a D-hexosamine sulfate, a flavonoid, L-adenosylmethionine, and a histamine-1-receptor antagonist, in an appropriate excipient or vehicle for oral or topical administration.

2. The composition according to claim 1, wherein said proteoglycan is selected from the group consisting of non-bovine chondroitin sulfate, keratan sulfate, dermatan sulfate and hyaluronic acid.

3. The composition according to claim 2, wherein said chondroitin sulfate is derived from shark cartilage.

4. The composition according to claim 1, wherein said hexosamine sulfate is D-glucosamine sulfate.

5. The composition according to claim 1, wherein said flavonoid is selected from the group consisting of quercetin, myricetin, genistein and kaempferol.

6. The composition according to claim 1, wherein said olive oil contains omega fatty acids and alpha-tocopherol.

7. The composition according to claim 24, said composition being for oral use, comprising 300 mg each of non-bovine chondroitin sulfate C, quercetin and D-glucosamine sulfate, in kernel olive oil.

8. The composition according to claims 7 or 24, further comprising 100 mg of L-adenosylmethionine.

D2 9. The composition according to claim 1, wherein said inflammatory disease is arthritis and said composition is contained in an ointment or cream for topical application, comprising, in mg%, chondroitin sulfate 0.05; unrefined kernel olive oil, 1-5; and one or more of D-glucosamine sulfate, 0.05; and quercetin, 0.03.

10. The composition according to claim 9, further comprising diphenhydramine, 5mg%.

D3 11. A composition according to claim 1, said composition consisting of a mouth wash composition, comprising chondroitin sulfate, 0.4 M; unrefined kernel olive oil 0.5-1.5 mg%; and one or more of D-glucosamine sulfate, 0.4 M; and quercetin, 0.3 M, in a mouth wash vehicle.

12. A composition according to claim 1, said composition consisting of a tooth paste, comprising, in mg%, chondroitin sulfate, 0.05; and unrefined kernel olive oil, 1-5; and one or more of D-glucosamine sulfate, 0.05; and quercetin, 0.03; in a tooth paste vehicle.

DS 13. A composition according to claim 1, said composition consisting of a sunscreen composition, comprising, in mg%, chondroitin sulfate, 0.05, and unrefined kernel oil, 1-5; and one or more of D-glucosamine sulfate, 0.05; quercetin, 0.03; and titanium dioxide, 1-5; in a sun screen vehicle.

22. A method of treating a subject suffering from an inflammatory disease, wherein said inflammatory disease results from biomolecules secreted from activated and degranulated mast cells, said inflammatory disease being selected from the group consisting of osteoarthritis, cancer, fibromyalgia, atherosclerosis, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, migraines, angina, chronic prostatitis, eczema, arthritis, multiple sclerosis, psoriasis, sun burn, and periodontal disease, comprising the step of administering to said subject an effective amount of a composition according to claim 1.

23. The composition according to claim 1, wherein said histamine-1-receptor antagonist is diphenhydramine.

24. The composition according to claim 1, wherein said inflammatory disease is arthritis and said composition is designed for oral administration, comprising non-bovine chondroitin sulfate, quercetin, D-glucosamine sulfate, and unrefined kernel olive oil.

25. The composition according to claim 9, comprising, in mg%, chondroitin sulfate, 0.05; D-glucosamine sulfate, 0.05; quercetin, 0.03; and, unrefined kernel olive oil, 1-5.

26. The composition according to claim 1 for oral use in allergic conditions, comprising chondroitin sulfate, a flavonoid selected from the group consisting of quercetin, myricetin and kaempferol, and said kernel olive oil.

27. The composition according to claim 26, comprising 200 mg each of chondroitin sulfate and kaempferol and said kernel olive oil.

DS 28. The composition according to claim 26, comprising chondroitin sulfate and myricetin and said kernel olive oil.

29. The composition according to claim 28, supplemented with a histamine-1-receptor antagonist.

30. The composition according to claim 29, wherein said antagonist is diphenhydramine.

31. The composition according to claim 1, wherein said inflammatory disease is cancer and wherein said composition is designed for oral use, comprising 25-50 mg of genistein and

illegible

150-300 mg of quercetin, and said kernel olive oil.


32. The composition according to claim 1, wherein said inflammatory disease is atherosclerosis with or without myocardial ischemia, comprising 100-300 mg each of chondroitin sulfate, myricetin and S-adenosylmethionine, and said kernel olive oil, in a vehicle for oral use.

33. The composition according to claim 1, wherein said inflammatory disease is interstitial cystitis, said composition comprising 100-300 mg of chondroitin sulfate, 100-300 mg of hyaluronic acid, and 200-400 mg quercetin, and said kernel olive oil, in a vehicle for oral use.

34. The composition according to claim 1, wherein said inflammatory disease is prostatitis, said composition comprising 100-200 mg of chondroitin sulfate, 100-200 mg hyaluronic acid and 200-400 mg of quercetin, and said kernel olive oil, in a vehicle for oral use.

35. The composition according to claim 1, wherein said inflammatory disease is multiple sclerosis, said composition comprising 100-300 mg each of chondroitin sulfate, myricetin and S-adenosylmethionine, and said kernel olive oil, in a vehicle for oral use.

illegible

Issue Classification 	Application No.	Applicant(s)	
	09/771,669	THEOHARIDES, THEOHARIS C.	
	Examiner	Art Unit	
	Sharon L. Howard	1615	

ISSUE CLASSIFICATION							
ORIGINAL		CROSS REFERENCE(S)					
CLASS	SUBCLASS	CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)				
514	886	424	49	464			
INTERNATIONAL CLASSIFICATION		514	887	901			
A01N	251.00						
A61K	7116						
A61K	9120						
	1						
	1						
Sharon Howard 7/19/04 (Assistant Examiner) (Date)		THURMAN K. PAGE SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600 (Date)			Total Claims Allowed: 32		
Mary Leeper 7/20/04 (Legal Instruments Examiner) (Date)					O.G. Print Claim(s) 1		O.G. Print Fig. —

<input type="checkbox"/> Claims renumbered in the same order as presented by applicant		<input type="checkbox"/> CPA		<input type="checkbox"/> T.D.		<input type="checkbox"/> R.1.47	
Final	Original	Final	Original	Final	Original	Final	Original
	1		31		61		91
	2		32		62		92
	3		33		63		93
	4		34		64		94
	5		35		65		95
	6		36		66		96
	7		37		67		97
	8		38		68		98
	9		39		69		99
	10		40		70		100
	11		41		71		101
	12		42		72		102
	13		43		73		103
	14		44		74		104
	15		45		75		105
	16		46		76		106
	17		47		77		107
	18		48		78		108
	19		49		79		109
	20		50		80		110
	21		51		81		111
	22		52		82		112
	23		53		83		113
	24		54		84		114
	25		55		85		115
	26		56		86		116
	27		57		87		117
	28		58		88		118
	29		59		89		119
	30		60		90		120
							121
							122
							123
							124
							125
							126
							127
							128
							129
							130
							131
							132
							133
							134
							135
							136
							137
							138
							139
							140
							141
							142
							143
							144
							145
							146
							147
							148
							149
							150
							151
							152
							153
							154
							155
							156
							157
							158
							159
							160
							161
							162
							163
							164
							165
							166
							167
							168
							169
							170
							171
							172
							173
							174
							175
							176
							177
							178
							179
							180
							181
							182
							183
							184
							185
							186
							187
							188
							189
							190
							191
							192
							193
							194
							195
							196
							197
							198
							199
							200
							201
							202
							203
							204
							205
							206
							207
							208
							209
							210